Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers.
Roohani S, Handtke J, Hummedah K, Albertsmeier M, Andreou D, Apostolidis L, Augustin M, Bauer S, Billner M, Bösch F, Deinzer CKW, Deventer N, Duprée A, Eckert F, Engel L, Fechner K, Fritzsche H, Gaidzik V, Ghani S, Grützmann R, Guder WK, Hamacher R, Hecker JS, Hendricks A, Hillmann A, Houben P, Hübner G, Ivanyi P, Jentsch C, Jordan M, Kappl P, Kaths M, Kessler T, Kirchberg J, Knebel C, Krempien R, Lehner B, Lenze U, Lindner LH, Lörsch AM, Maguire N, Müller S, Piso P, Potkrajcic V, Reichardt P, Richter S, Schewe S, Schiffmann LM, Scholten F, Striefler JK, Schwarzbach M, Seidensaal K, Semrau S, Szkandera J, Szuszies CJ, Timmermann B, Tuscherer A, Wiegering A, Winkelmann MT, Kaul D, Jakob J. Roohani S, et al. Among authors: augustin m. J Cancer Res Clin Oncol. 2025 Jan 4;151(1):30. doi: 10.1007/s00432-024-06063-z. J Cancer Res Clin Oncol. 2025. PMID: 39755880 Free PMC article.
Systematic assessment of COVID-19 host genetics using whole genome sequencing data.
Schmidt A, Casadei N, Brand F, Demidov G, Vojgani E, Abolhassani A, Aldisi R, Butler-Laporte G; DeCOI host genetics group; Alawathurage TM, Augustin M, Bals R, Bellinghausen C, Berger MM, Bitzer M, Bode C, Boos J, Brenner T, Cornely OA, Eggermann T, Erber J, Feldt T, Fuchsberger C, Gagneur J, Göpel S, Haack T, Häberle H, Hanses F, Heggemann J, Hehr U, Hellmuth JC, Herr C, Hinney A, Hoffmann P, Illig T, Jensen BO, Keitel V, Kim-Hellmuth S, Koehler P, Kurth I, Lanz AL, Latz E, Lehmann C, Luedde T, Maj C, Mian M, Miller A, Muenchhoff M, Pink I, Protzer U, Rohn H, Rybniker J, Scaggiante F, Schaffeldt A, Scherer C, Schieck M, Schmidt SV, Schommers P, Spinner CD, Vehreschild MJGT, Velavan TP, Volland S, Wilfling S, Winter C, Richards JB; DeCOI; Heimbach A, Becker K, Ossowski S, Schultze JL, Nürnberg P, Nöthen MM, Motameny S, Nothnagel M, Riess O, Schulte EC, Ludwig KU. Schmidt A, et al. Among authors: augustin m. PLoS Pathog. 2024 Dec 23;20(12):e1012786. doi: 10.1371/journal.ppat.1012786. eCollection 2024 Dec. PLoS Pathog. 2024. PMID: 39715278 Free PMC article.
Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study).
Wilsmann-Theis D, Patt S, Pinter A, Gerdes S, Magnolo N, Németh R, Schmitz J, Paul C, Augustin M, Staubach P, Weyergraf A, Hüffmeier U, Wolk K, Sabat R, Mößner R. Wilsmann-Theis D, et al. Among authors: augustin m. JAAD Int. 2024 Oct 2;18:69-78. doi: 10.1016/j.jdin.2024.09.001. eCollection 2025 Feb. JAAD Int. 2024. PMID: 39618912 Free PMC article.
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.
Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG; OLYMPIA 1 Investigators. Ständer S, et al. Among authors: augustin m. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4796. Online ahead of print. JAMA Dermatol. 2024. PMID: 39602139
Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year.
Mostaghimi A, Augustin M, Harada K, Senna M, Dutronc Y, Yu G, Ball S, Murage M, Kolodsick J, Brogan Y, King B. Mostaghimi A, et al. Among authors: augustin m. J Eur Acad Dermatol Venereol. 2024 Nov 21. doi: 10.1111/jdv.20334. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39569884 No abstract available.
1,227 results